Deniz Gezgin YILDIRIM, Sevcan A. BAKKALOĞLU, A. Şebnem SOYSAL ACAR, Necla BUYAN

Parental knowledge about familial Mediterranean fever: a cross-sectional study

Background. The life-long course, long-term complications, necessity for regular treatment, and potential side effects of the medications must be well understood by parents of pediatric familial Mediterranean fever (FMF) patients. The aim of this study was to assess parental knowledge and to investigate how parents obtained scientific information about FMF. Methods. One hundred and seventy-one pediatric FMF patients and their parents were enrolled in this cross- sectional study. Three-part questionnaires, including forms on socio-demographics, knowledge and perceptions of FMF, and how to get information about FMF, were administered to parents. Results. In the analysis of the knowledge questions, 90.1% of parents were aware of colchicine as an effective drug for FMF, but only 39.2% of them were aware that there is no vital risk during FMF attacks. Caregivers preferred to obtain information from physicians (98.8%), websites (47.9%), seminars (3.5%), and books (1.7%). The knowledge scores of parents were significantly higher among those whose children were using anti- interleukin-1 therapy in addition to colchicine relative to those on colchicine alone (p = 0.04). There was a positive correlation between knowledge level and parental educational status (p = 0.0001). Conclusions. Knowledge scores among parents of pediatric FMF patients are unsatisfactory. The parents whose children have a severe disease course and a need for anti-interleukin-1 therapy are more knowledgeable. For parents, continuing education programs including books, seminars and web-sites giving information about the course, prognosis, complications and treatments of FMF should be employed immediately after the diagnosis and thereafter.

PDF

___

1. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998; 351: 659-664. https://doi.org/10.1016/ S0140-6736(97)09408-7

2. Bernot A, Clepet C, Dasilva C, et al; French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25-31. https://doi.org/10.1038/ng0997-25

3. Tunca M; Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84: 1-11. https://doi.org/10.1097/01. md.0000152370.84628.0c

4. Onen F. Familial Mediterranean fever. Rheumatol Int 2006; 26: 489-496. https://doi.org/10.1007/s00296- 005-0074-3

5. Alghamdi M. Familial Mediterranean fever, review of the literature. Clin Rheumatol 2017; 36: 1707-1713. https://doi.org/10.1007/s10067-017-3715-5

6. Wickwar S, Buerkle K, McBain H, et al. Adaptation of the methotrexate in rheumatoid arthritis knowledge questionnaire (MiRAK) for use with parents of children with juvenile idiopathic arthritis: a qualitative study. Pediatr Rheumatol Online J 2013; 11: 27. https://doi.org/10.1186/1546-0096-11-27

7. Al-Eid WM, Madi SM, Bahabri SA, Al-Mayouf SM. Evaluation of parental knowledge of Pediatric Rheumatic Diseases. Saudi Med J 2001; 22: 531-536.

8. Rani A, Thomas PT. Parental knowledge, attitude, and perception about epilepsy and sociocultural barriers to treatment. J Epilepsy Res 2019; 9: 65-75. https://doi.org/10.14581/jer.19007

9. Mat MAC, Yaacob LH, Zakaria R. Parental knowledge on thalassaemia and factors associated with refusal to screen their children. Malays J Med Sci 2020; 27: 124-133. https://doi.org/10.21315/ mjms2020.27.1.13

10. Solem EP, Primiano M, McQuillen MP, Zak Goelz M. Factors associated with parental knowledge of neurofibromatosis type 1 (NF1): parental affected status and genetic counseling. J Genet Couns 2020 29: 1151-1158. https://doi.org/10.1002/jgc4.1275

11. Chan KH, Panoch J, Carroll A, Wiehe S, Cain MP, Frankel R. Knowledge gaps and information seeking by parents about hypospadias. J Pediatr Urol 2020; 16: 166.e1-166.e8. https://doi.org/10.1016/j. jpurol.2020.01.008

12. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med 1967; 43: 227-253. https://doi.org/10.1016/0002-9343(67)90167-2

13. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016; 75: 644-651. https://doi.org/10.1136/ annrheumdis-2015-208690

14. Pras E, Livneh A, Balow JE Jr, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet 1998; 75: 216-219. https://doi.org/10.1002/(SICI)1096- 8628(19980113)75:2<216::AID-AJMG20>3.0.CO;2-R

15. Köhler BM, Lorenz HM, Blank N. IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. Eur J Rheumatol 2018; 5: 230- 234. https://doi.org/10.5152/eurjrheum.2018.18036

16. Koşan Z, Yılmaz S, Yerli EB, Köyceğiz E. Evaluation of the burden of care and the quality of life in the parents of Turkish children with familial Mediterranean fever. J Pediatr Nurs 2019; 48: e21-e26. https://doi.org/10.1016/j.pedn.2019.05.017

17. Turan Gürhopur FD, Işler Dalgiç A. The effect of a modular education program for children with epilepsy and their parents on disease management. Epilepsy Behav 2018; 78: 210-218. https://doi. org/10.1016/j.yebeh.2017.07.048

18. Kinkar A, Alqarni D, Alghamdi A, et al. Parental knowledge, attitudes, and behaviors toward their epileptic children at King Abdulaziz University Hospital: cross-sectional study. Interact J M